Top Midday Decliners

MT Newswires Live

16 hours ago

Alumis (ALMS) said Tuesday that a phase 2 study of its envudeucitinib experimental drug in moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints in the overall trial population.

Shares slumped nearly 59% as intraday trading volume catapulted to over 20.9 million from a daily average of about 1.3 million.

Enovis (ENOV) has signed a binding offer to acquire eCential Robotics for 176 million euros ($204 million) in cash, plus up to 35 million euros in milestone payments, the company said Tuesday.

BMO Capital adjusted the Enovis price target to $27 from $30, while maintaining its outperform rating.

Shares dropped 10% as intraday trading volume climbed to over 1.9 million from a daily average of about 1.1 million.

Cango (CANG) reported a Q2 loss from continuing operations late Monday while revenue more than halved.

Shares slumped 22%, with intraday trading volume at over 419,000, versus a daily average of about 259,000.

Price: 9.00, Change: -12.81, Percent Change: -58.73

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/news/2664371865"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664371865\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664371865?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 02:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664371865","market":"hk","top_or_hot":-1,"title":"Top Midday Decliners","media":"MT Newswires Live","content":"<html><body><p> Alumis (ALMS) said Tuesday that a phase 2 study of its envudeucitinib experimental drug in moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints in the overall trial population.</p><p>Shares slumped nearly 59% as intraday trading volume catapulted to over 20.9 million from a daily average of about 1.3 million.</p><p>Enovis (ENOV) has signed a binding offer to acquire eCential Robotics for 176 million euros ($204 million) in cash, plus up to 35 million euros in milestone payments, the company said Tuesday.</p><p>BMO Capital adjusted the Enovis price target to $27 from $30, while maintaining its outperform rating.</p><p>Shares dropped 10% as intraday trading volume climbed to over 1.9 million from a daily average of about 1.1 million.</p><p>Cango (CANG) reported a Q2 loss from continuing operations late Monday while revenue more than halved.</p><p>Shares slumped 22%, with intraday trading volume at over 419,000, versus a daily average of about 259,000.</p><p>Price: 9.00, Change: -12.81, Percent Change: -58.73</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Decliners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Decliners\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-02 02:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Alumis (ALMS) said Tuesday that a phase 2 study of its envudeucitinib experimental drug in moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints in the overall trial population.</p><p>Shares slumped nearly 59% as intraday trading volume catapulted to over 20.9 million from a daily average of about 1.3 million.</p><p>Enovis (ENOV) has signed a binding offer to acquire eCential Robotics for 176 million euros ($204 million) in cash, plus up to 35 million euros in milestone payments, the company said Tuesday.</p><p>BMO Capital adjusted the Enovis price target to $27 from $30, while maintaining its outperform rating.</p><p>Shares dropped 10% as intraday trading volume climbed to over 1.9 million from a daily average of about 1.1 million.</p><p>Cango (CANG) reported a Q2 loss from continuing operations late Monday while revenue more than halved.</p><p>Shares slumped 22%, with intraday trading volume at over 419,000, versus a daily average of about 259,000.</p><p>Price: 9.00, Change: -12.81, Percent Change: -58.73</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENOV","symbol_name":"Enovis Corporation","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664371865","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664371865","pubTimestamp":1788286893,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alumis  said Tuesday that a phase 2 study of its envudeucitinib experimental drug in moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints in the overall trial population.Shares slumped nearly 59% as intraday trading volume catapulted to over 20.9 million from a daily average of about 1.3 million.Enovis  has signed a binding offer to acquire eCential Robotics for 176 million euros  in cash, plus up to 35 million euros in milestone payments, the company said Tuesday.BMO Capital adjusted the Enovis price target to $27 from $30, while maintaining its outperform rating.Shares dropped 10% as intraday trading volume climbed to over 1.9 million from a daily average of about 1.1 million.Cango  reported a Q2 loss from continuing operations late Monday while revenue more than halved.Shares slumped 22%, with intraday trading volume at over 419,000, versus a daily average of about 259,000.Price: 9.00, Change: -12.81, Percent Change: -58.73","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ENOV":"Enovis Corporation","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4214":"汽车零售","BK4023":"应用软件","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","ALMS":"Alumis Inc.","BK4082":"医疗保健设备","BK4122":"互联网与直销零售","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4600":"加密货币概念","BK4007":"制药","CANG":"灿谷"},"translate_title":"午盘跌幅最大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CANG":1,"ENOV":1,"ALMS":1},"content_text":"Alumis (ALMS) said Tuesday that a phase 2 study of its envudeucitinib experimental drug in moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints in the overall trial population.Shares slumped nearly 59% as intraday trading volume catapulted to over 20.9 million from a daily average of about 1.3 million.Enovis (ENOV) has signed a binding offer to acquire eCential Robotics for 176 million euros ($204 million) in cash, plus up to 35 million euros in milestone payments, the company said Tuesday.BMO Capital adjusted the Enovis price target to $27 from $30, while maintaining its outperform rating.Shares dropped 10% as intraday trading volume climbed to over 1.9 million from a daily average of about 1.1 million.Cango (CANG) reported a Q2 loss from continuing operations late Monday while revenue more than halved.Shares slumped 22%, with intraday trading volume at over 419,000, versus a daily average of about 259,000.Price: 9.00, Change: -12.81, Percent Change: -58.73","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}